Understanding the biopsychosocial factors contributing to mental health issues in Fabry disease: One tertiary centre experience

Forshaw-Hulme, Stuart; Gorton, Janet; McGrae, Tracey; Thompson, Lorraine; Chen, Cliff; Roberts, Mark W.; Jovanović, Ana; Sharma, Reena; Wilcox, Gisela; Adrees, Faiza; Kempshall, Stephen; Stępień, Karolina M.

doi:10.1016/j.ymgme.2019.11.133

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pain is a significant contributory factor to depression [85] and anxiety [8,23]. However, biopsychosocial factors may also contribute to the mood disorder in Fabry disease [86]. Overall, it is estimated that Fabry patients experience higher rates of depression (27-57% of patients) compared to the general population (7-27%) [23,85].…”

Section: Mental Health and Pain In Fabry Diseasementioning

confidence: 99%

Review of Mechanisms, Pharmacological Management, Psychosocial Implications, and Holistic Treatment of Pain in Fabry Disease

Rajan

Ireland

Johnson

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Fabry disease is a progressive X-linked lysosomal storage disease caused by a mutation in the GLA gene, encoding the lysosomal hydrolase α-galactosidase A. The consequent reduced enzyme activity results in the toxic accumulation of glycosphingolipids, particularly globortriaosylceramide (Gb3 or GL3), in blood vessels, renal epithelia, myocardium, peripheral nervous system, cornea and skin. Neuropathic pain is the most common manifestation of Fabry disease and can be extremely debilitating. This often develops during childhood and presents with episodes of burning and sharp pain in the hands and feet, especially during exercise and it is worse with increased heat or fever. It is thought to be due to ischaemic injury and metabolic failure, leading to the disruption of neuronal membranes and small fibre neuropathy, caused by a reduced density of myelinated Aδ and unmyelinated C-fibres and alterations in the function of ion channels, mediated by Gb3 and lyso Gb3. It is important to confirm small fibre neuropathy before any Fabry disease treatment modality is considered. There is a clinical need for novel techniques for assessing small fibre function to improve detection of small fibre neuropathy and expand the role of available therapies. The current Fabry disease guidelines are in favour of pharmacological management as the first-line treatment for pain associated with Fabry disease. Refractory cases would benefit from a rehabilitation approach with interdisciplinary input, including medical, physiotherapy and psychological disciplines and including a Pain Management Programme.

show abstract